Bristol-Myers drug fails lung cancer study, shares plunge

NEW YORK (AP) — A blockbuster cancer treatment failed in a key study as the drug's maker, Bristol-Myers Squibb, attempts to extend its usage for lung cancer patients.

Bristol's drug, Opdivo, and Merck's drug Keytruda are immunotherapies, which bolster the immune system so that patients can better fight cancer.